Characteristic | Donepezil/placebo (n = 9) | Placebo/donepezil (n = 10) | ||
---|---|---|---|---|
Values are mean (SD). ADAScog, Alzheimer’s disease rating scale, cognitive scale (higher scores indicate more impairment); MDRS, Mattis Dementia Rating Scale (lower scores worse); MMSE, Mini Mental Status (lower scores worse); UPDRS, Unified Parkinson’s Disease Rating Scale (higher scores worse). COMT, catechol-O-methyltransferase. | ||||
Age | 75.0 (9.8) | 72.1 (8.1) | ||
M/F | 9/0 | 6/4 | ||
ADAScog total | 29.5 (13.5) | 32.3 (9.5) | ||
MMSE | 23.1 (2.5) | 21.4 (3.4) | ||
Total UPDRS | 64.9 (25.9) | 65.8 (21.7) | ||
Motor UPDRS | 41.2 (17.4) | 41.2 (17.6) | ||
Duration of PD | 7.1 (2.6) | 14.4 (13.1) | ||
Use of levodopa (+/− COMT inhibitor) | 10 | 9 | ||
Use of dopamine agonsits | 3 | 3 | ||
Use of selegiline | 0 | 0 | ||
Use of neuroleptic (quetiapine) | 4 | 3 |